$ABP
Abpro Holdings, Inc. Stock $abp

$abp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024102370 Filed on November 26, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses			$260.0K
YoY Change			-51.63%
Operating Profit		-$391.7K	-$1.141M
YoY Change		24.25%	112.27%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$84.24K	$96.48K
YoY Change		-77.02%	-97.07%
Pretax Income		-$307.4K	-$1.045M
YoY Change		-698.44%	-137.98%
Income Tax		$27.65K	$4.140K
% Of Pretax Income
Net Earnings		-$335.1K	-$1.049M
YoY Change		650.84%	-150.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	51.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$13.60K	$10.61K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$20.25K	$15.14K
Receivables
Other Receivables
Total Short-Term Assets	$1.560M	$25.76K
YoY Change	48.08%	-95.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$30.00M
YoY Change	-17.73%
Other Assets
YoY Change
Total Long-Term Assets	$6.298M	$7.508M
YoY Change	-82.73%	-97.6%
TOTAL ASSETS
Total Short-Term Assets	$1.560M	$25.76K
Total Long-Term Assets	$6.298M	$7.508M
Total Assets	$7.858M	$7.534M
YoY Change	-79.06%	-97.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.041M	$6.605M
YoY Change	64.12%	109.13%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.041M	$6.605M
Total Long-Term Liabilities
Total Liabilities	$19.54M	$17.11M
YoY Change	22.06%	25.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.81M	-$16.99M
YoY Change	18.28%	45.62%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.81M	-$16.99M
YoY Change
Total Liabilities & Shareholders Equity	$7.858M	$7.534M
YoY Change	-79.06%	-97.6%

Cashflow Statement

Concept	2024 Q3	2024 Q1
OPERATING ACTIVITIES
Net Income	-$335.1K	-$1.049M
YoY Change	650.84%	-150.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$263.9K
YoY Change		171.47%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$29.69M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$29.73M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-29.68M
YoY Change
NET CHANGE
Cash From Operating Activities		-263.9K
Cash From Investing Activities		29.69M
Cash From Financing Activities		-29.68M
Net Change In Cash		-253.9K
YoY Change		161.18%
FREE CASH FLOW
Cash From Operating Activities		-$263.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41224
	dei	Entity Registrant Name EntityRegistrantName	ABPRO HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1013956
	dei	Entity Address Address Line1 EntityAddressAddressLine1	68 Cummings Park Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
	dei	Entity Address Country EntityAddressCountry	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
	dei	City Area Code CityAreaCode	(248)
	dei	Local Phone Number LocalPhoneNumber	890-7200
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51518605	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13597	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	264538	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20250	usd
CY2024Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	1423594	usd
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	29728990	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1560441	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	29993528	usd
CY2024Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	6297612	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	7372451	usd
CY2024Q3	us-gaap	Assets Assets	7858053	usd
CY2023Q4	us-gaap	Assets Assets	37365979	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1739989	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	469268	usd
CY2024Q3	acab	Excise Tax Payable Current ExciseTaxPayableCurrent	3076240	usd
CY2023Q4	acab	Excise Tax Payable Current ExciseTaxPayableCurrent	3062004	usd
CY2024Q3	acab	Accrued Offering Costs AccruedOfferingCosts	5000	usd
CY2023Q4	acab	Accrued Offering Costs AccruedOfferingCosts	5000	usd
CY2024Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	366161	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	308194	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2270051	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1655000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9041035	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35388456	usd
CY2024Q3	acab	Deferred Underwriting Fee Payable Non Current DeferredUnderwritingFeePayableNonCurrent	10500000	usd
CY2023Q4	acab	Deferred Underwriting Fee Payable Non Current DeferredUnderwritingFeePayableNonCurrent	10500000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	19541035	usd
CY2023Q4	us-gaap	Liabilities Liabilities	45888456	usd
CY2024Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	541269	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	541269	shares
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	541269	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	541269	shares
CY2024Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	11.32
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.93
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6127635	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7292641	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17811367	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15815868	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-17810617	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15815118	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7858053	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37365979	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	391686	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	315247	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1926428	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1273146	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-391686	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-315247	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1926428	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1273146	usd
CY2024Q3	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	2078	usd
CY2023Q3	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	25961	usd
	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	2964	usd
	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	43744	usd
CY2024Q3	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	82162	usd
CY2023Q3	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	468307	usd
	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	258756	usd
	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	5279395	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	127646	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	127646	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	84240	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	366622	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	261720	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5195493	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-307446	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	51375	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1664708	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3922347	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27654	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96005	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57967	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1093646	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-335100	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-44630	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1722675	usd
	us-gaap	Net Income Loss NetIncomeLoss	2828701	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15815118	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	121197	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1048724	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-16985039	usd
CY2024Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	73483	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-338851	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-17397373	usd
CY2024Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	63908	usd
CY2024Q3	acab	Adjustments To Additional Paid In Capital Excise Tax AdjustmentsToAdditionalPaidInCapitalExciseTax	-14236	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-335100	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-17810617	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11179412	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2554544	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	2070528	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11663428	usd
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1180703	usd
CY2023Q2	acab	Adjustments To Additional Paid In Capital Stockholder Nonredemption Agreement AdjustmentsToAdditionalPaidInCapitalStockholderNonredemptionAgreement	1378126	usd
CY2023Q2	acab	Adjustments To Additional Paid In Capital Stockholder Nonredemption Agreement Reduce AdjustmentsToAdditionalPaidInCapitalStockholderNonredemptionAgreementReduce	-1378126	usd
CY2023Q2	acab	Adjustments To Additional Paid In Capital Excise Tax AdjustmentsToAdditionalPaidInCapitalExciseTax	-2764714	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	802803	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-14806042	usd
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	207556	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-44630	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15058228	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1722675	usd
	us-gaap	Net Income Loss NetIncomeLoss	2828701	usd
	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	258756	usd
	acab	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	5279395	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	123250	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-272145	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1270722	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-528026	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	57967	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1200013	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-775992	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1506562	usd
	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments	90000	usd
	acab	Proceeds From Trust Account To Pay Franchise And Income Taxes ProceedsFromTrustAccountToPayFranchiseAndIncomeTaxes	2132269	usd
	acab	Proceeds From Trust Account In Connection With Redemption ProceedsFromTrustAccountInConnectionWithRedemption	29728990	usd
	acab	Proceeds From Trust Account In Connection With Redemption ProceedsFromTrustAccountInConnectionWithRedemption	276471460	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29638990	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	278603729	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	615051	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	70000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	29728990	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	276471460	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29113939	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-276541460	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-250941	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	555707	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264538	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	392446	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13597	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	948153	usd
	acab	Remeasurement Of Carrying Value To Redemption Value RemeasurementOfCarryingValueToRedemptionValue	258588	usd
	acab	Remeasurement Of Carrying Value To Redemption Value RemeasurementOfCarryingValueToRedemptionValue	3942803	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	61009	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	983333	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	200000	shares
CY2024Q3	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	291667	shares
CY2024Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	14300000	usd
	acab	Received Shares ReceivedShares	600601	shares
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	2000000	usd
CY2024Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	3000000	usd
CY2024Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2755000	usd
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.94	pure
	acab	Number Of Consecutive Trading Days NumberOfConsecutiveTradingDays	P5Y
	acab	Shares Issued Transaction Costs SharesIssuedTransactionCosts	17204107	usd
	acab	Shares Issued Underwriting Fees SharesIssuedUnderwritingFees	5760000	usd
	acab	Cash Discount On Underwriting Fees CashDiscountOnUnderwritingFees	240000	usd
	acab	Shares Issued Deferred Underwriting Fees SharesIssuedDeferredUnderwritingFees	10500000	usd
	acab	Shares Issued Other Offering Costs SharesIssuedOtherOfferingCosts	944107	usd
CY2022Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	306000000	usd
CY2022Q1	acab	Cash Held In Trust Account Equivalent To Units Price Per Unit CashHeldInTrustAccountEquivalentToUnitsPricePerUnit	10.2
	acab	Completion Of Business Combination Available Term CompletionOfBusinessCombinationAvailableTerm	P15M
CY2023Q4	acab	Minimum Amount To Be Kept In Trust Account Up To Business Combination MinimumAmountToBeKeptInTrustAccountUpToBusinessCombination	30000	usd
CY2023Q4	acab	Minimum Amount To Be Kept In Trust Account Up To Business Combination Price Per Share MinimumAmountToBeKeptInTrustAccountUpToBusinessCombinationPricePerShare	0.045
CY2023Q4	acab	Common Stock Subject To Redemption Value CommonStockSubjectToRedemptionValue	29728990	usd
CY2024Q1	acab	Waiver Of Underwriting Fee Amount WaiverOfUnderwritingFeeAmount	4290000	usd
CY2024Q1	acab	Exchange Of Shares ExchangeOfShares	600000	shares
CY2024Q2	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
CY2024Q2	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
CY2024Q2	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
CY2024Q3	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
CY2024Q3	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
CY2024Q3	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	10000	usd
	acab	Accrue Interest Percentage AccrueInterestPercentage	0.075	pure
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1100000	shares
	acab	Payments For Extending Business Combination PaymentsForExtendingBusinessCombination	16238	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	30000000	usd
CY2024Q3	acab	Aggregate Purchase Price AggregatePurchasePrice	5000000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1000000	shares
CY2024Q3	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	2000000	usd
CY2024Q3	acab	Percentage Of Redeem Or Repurchase Of Common Stock PercentageOfRedeemOrRepurchaseOfCommonStock	1	pure
CY2024Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1423594	shares
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	11.29
CY2024Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1423594	shares
CY2024Q3	us-gaap	Cash Cash	13597	usd
CY2024Q3	acab	Working Capital Deficit WorkingCapitalDeficit	7480594	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.01	pure
CY2022Q3	acab	Percentage Of Fair Market Value On Excise Tax PercentageOfFairMarketValueOnExciseTax	0.01	pure
	acab	Percentage Of Interest And Penalty Rate PercentageOfInterestAndPenaltyRate	0.10	pure
	acab	Percentage Of Underpayment Penalty Per Month PercentageOfUnderpaymentPenaltyPerMonth	0.05	pure
	acab	Percentage Of Liability Total PercentageOfLiabilityTotal	0.25	pure
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	126122	shares
CY2024Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1423594	shares
	acab	Excise Tax Liability ExciseTaxLiability	3076240	usd
CY2023	acab	Excise Tax Liability ExciseTaxLiability	3062004	usd
CY2023	acab	Percentage Of Shares Redeemed PercentageOfSharesRedeemed	0.01	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13597	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	264538	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	260000	usd
	us-gaap	Operating Expenses OperatingExpenses	260000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	300000000	usd
CY2022	acab	Proceeds Allocated To Public Warrants ProceedsAllocatedToPublicWarrants	-8100000	usd
CY2022	acab	Common Stock Issuance Costs CommonStockIssuanceCosts	-16699058	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	33896988	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	309097930	usd
CY2023	acab	Temporary Equity Redemption Value TemporaryEquityRedemptionValue	-276471460	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	29728990	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4395161	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7292641	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	121197	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7413838	usd
CY2024Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	73483	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7487321	usd
CY2024Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1423594	usd
CY2024Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	63908	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6127635	usd
CY2022Q1	acab	Offering Costs OfferingCosts	17204107	usd
CY2022Q1	acab	Offering Costs Allocated In Temporary Equity OfferingCostsAllocatedInTemporaryEquity	16699058	usd
CY2022Q1	acab	Offering Costs Allocated In Shareholders Equity OfferingCostsAllocatedInShareholdersEquity	505049	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0899	pure
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.8687	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0348	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2788	pure
CY2024Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3224	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3224	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	28850000	shares
	acab	Disclosure Of Initial Public Offering DisclosureOfInitialPublicOffering	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>NOTE 3. INITIAL PUBLIC OFFERING</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in; text-align: justify">Pursuant to the Initial Public Offering, the Company sold 30,000,000 Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company’s Series A common stock and one-half of one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one share of Series A common stock at an exercise price of $11.50 per whole share (see Note 7).</p>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	50000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	362500	usd
CY2024Q3	acab	Promissory Note Amount PromissoryNoteAmount	103000	usd
CY2024Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	206000	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	103000	usd
	acab	Underwriting Discount Per Share UnderwritingDiscountPerShare	0.2
	acab	Cash Underwriting Discount CashUnderwritingDiscount	6000000	usd
	acab	Underwriters Deferred Fee Per Unit UnderwritersDeferredFeePerUnit	0.35
	acab	Underwriters Deferred Fee UnderwritersDeferredFee	10500000	usd
CY2024Q1	acab	Percentage Of Gross Amount Payable To Sponsor Raised From Investors PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors	0.04	pure
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	5000001	usd
CY2024Q3	acab	Minimum Cash And Cash Equivalents Needed To Consummate Business Combination MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination	8700000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	541269	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	541269	shares
	acab	Number Of Days After Consummation Of Business Combination With In Which The Securities Shall Be Registered NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered	P20D
	acab	Number Of Days After Which Business Combination With In Which Securities Registration Shall Be Effective NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective	P60D
	acab	Percentage Of Market Value And Newly Issued Price PercentageOfMarketValueAndNewlyIssuedPrice	1.15	pure
CY2024Q3	acab	Additional Shares Issued AdditionalSharesIssued	14500000	shares
CY2024Q3	acab	Sponser Agreement Description SponserAgreementDescription	(i) retain 2,950,000 shares of Series A Common Stock of ACAB, (ii) retain 291,667 shares, and transfer 983,333 shares to Abpro and 983,333 of the shares Abpro Bio, for such parties to use to obtain non-redemption commitments from SPAC stockholders or other capital for SPAC or the Surviving Corporation (with any shares unused for such purpose to be retained by such party), and (iii) forfeit the remainder of any Series A Common Stock and Series B Common Stock held by Sponsor (or 966,441 Series A shares and 1 Series B shares).
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	200000	shares
CY2024Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	14300000	usd
CY2024Q3	acab	Promissory Note Liabilities PromissoryNoteLiabilities	2000000	usd
CY2024Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.94	pure
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments		usd
	acab	Proceeds From Trust Account To Pay Franchise And Income Taxes ProceedsFromTrustAccountToPayFranchiseAndIncomeTaxes		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001893219

Files In Submission

Name	View Source	Status
0001213900-24-102370-index-headers.html	Edgar Link	pending
0001213900-24-102370-index.html	Edgar Link	pending
0001213900-24-102370.txt	Edgar Link	pending
0001213900-24-102370-xbrl.zip	Edgar Link	pending
acab-20240930.xsd	Edgar Link	pending
ea0221502-10q_abprohold.htm	Edgar Link	pending
ea022150201ex31-1_abprohold.htm	Edgar Link	pending
ea022150201ex31-2_abprohold.htm	Edgar Link	pending
ea022150201ex32-1_abprohold.htm	Edgar Link	pending
ea022150201ex32-2_abprohold.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
acab-20240930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
acab-20240930_lab.xml	Edgar Link	unprocessable
acab-20240930_pre.xml	Edgar Link	unprocessable
ea0221502-10q_abprohold_htm.xml	Edgar Link	completed
acab-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABP
Abpro Holdings, Inc. Stock $abp

2024 Q4 Form 10-Q Financial Statement

#000121390024102370 Filed on November 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABP Abpro Holdings, Inc. Stock $abp

2024 Q4 Form 10-Q Financial Statement

#000121390024102370 Filed on November 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABP
Abpro Holdings, Inc. Stock $abp